Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19

Author:

Close Ryan M.1,Jones T. Shaifer1,Jentoft Christopher1,McAuley James B.1

Affiliation:

1. Whiteriver Indian Hospital, Indian Health Service, Whiteriver, Arizona

Publisher

American Medical Association (AMA)

Subject

General Medicine

Reference6 articles.

1. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial.;Gottlieb;JAMA,2021

2. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19.;Weinreich;N Engl J Med,2021

3. Infectious disease mortality among American Indians and Alaska Natives, 1999-2009.;Cheek;Am J Public Health,2014

4. COVID-19 mortality among American Indian and Alaska Native persons—14 states, January-June 2020.;Arrazola;MMWR Morb Mortal Wkly Rep,2020

5. US Food and Drug Administration. Fact sheet for health care providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. November 9, 2020. Updated May 14, 2021. Accessed January 29, 2021. https://www.fda.gov/media/145802/download

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3